In this project we intend to analyze the microbiome. This procedure could help us in the future to avoid BCG therapy in patients with a high risk of therapy failure and save time to start alternative therapy options and hopefully prevent tumor progression.
Aim of the study
With this study, we want to investigate whether the microbiome, i.e. the entirety of the bacteria colonized in the digestive tract and in the bladder, differs in bladder cancer patients who successfully respond to the so-called BCG immunotherapy compared to patients who do not respond or do not tolerate the therapy and suffer side effects. We will also take various samples from patients who do not require BCG immunotherapy and patients without bladder cancer for studies that will be carried out at a later date. Among other things, these follow-up projects will look at whether the microbiome may be involved in the development of cancer.
Who can take part?
Patients undergoing bladder surgery or transurethral resection of the prostate, patients with non-muscle-invasive bladder cancer
Procedure
Your study doctor and the study team will inform you in detail about the course of the study.
Compensation
None
Original study name
Towards individualization of bladder cancer therapy: the role of the microbiome in predicting response to BCG
BASEC number
2021-01783
Financial support from
University Hospital Zurich